From Positive Proof of Concept to Phase III Registration Trial: Designing & Executing Robust Clinical Trials in Rare Disease Indications

Time: 8:00 am
day: Day Two


• Accelerating development of BION-1301 for the treatment of IgAN
• Exploring disease-modifying biomarkers assessments and optimizing trial design in rare disease populations
• To orphan drug designation and beyond: enhancing clinical outcome in defined patient cohorts